Biogen Inc (BIIB)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | 1,161,100 | 3,046,900 | 1,556,100 | 4,000,600 | 5,888,500 |
| Total stockholders’ equity | US$ in thousands | 14,799,400 | 13,397,900 | 10,896,200 | 10,700,300 | 13,343,200 |
| ROE | 7.85% | 22.74% | 14.28% | 37.39% | 44.13% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $1,161,100K ÷ $14,799,400K
= 7.85%
Biogen Inc's return on equity (ROE) has shown a declining trend over the past five years. The ROE decreased significantly from 44.13% in 2019 to 7.85% in 2023. This decline suggests that the company's ability to generate profits from its shareholders' equity has weakened over time. Factors contributing to the decline in ROE may include changes in the company's profitability, asset management efficiency, or financial leverage. It is essential for Biogen Inc to analyze the underlying reasons for the decreasing ROE and take appropriate measures to improve its performance and shareholder value in the future.
Peer comparison
Dec 31, 2023